About 70% of affected individuals harbor the p.Gly406Arg gain-of-function mutation in the CACNA1C gene (Timothy Syndrome Type 1, TS1), which has been shown to impair the voltage-dependent inactivation (VDI) of the LTCC and thus prolong action potentials (APs)1. Here, CACNA1C is linked to Timothy syndrome type 1.